Mia's Feed
Medical News & Research

Encouraging Outcomes of CAR T-cell Therapy for Leukemia and Lymphoma in Sweden

Encouraging Outcomes of CAR T-cell Therapy for Leukemia and Lymphoma in Sweden

Share this article

Swedish research reports improved survival rates and fewer side effects in leukemia and lymphoma patients receiving CAR T-cell therapy, marking a significant advancement in cancer immunotherapy.

2 min read

Recent advancements in immunotherapy have shown promising results with CAR T-cell treatment for patients suffering from certain blood cancers. A comprehensive analysis conducted within the Swedish SWECARNET network highlights that patients with aggressive B-cell lymphoma (ABCL) treated with CAR T-cell therapy exhibit improved survival rates and experience fewer severe side effects than previously recorded in early trials. The study, published in the journal Leukemia, encompasses data from 93 adult patients treated between 2019 and 2024.

The findings reveal that approximately 66% of these patients achieved complete remission, with no detectable cancer within 30 days post-treatment. Moreover, over half of these patients, about 53%, remained in remission one year after therapy. Interestingly, the study found no significant difference in treatment outcomes between older and younger patients, indicating that age may not be a limiting factor for this advanced therapy.

Since Uppsala University Hospital pioneered the first European clinical trial of CAR T-cell therapy for B-cell lymphoma, Sweden has become a leader in this innovative treatment approach. The advancements are attributed not only to improvements in the therapy itself but also to better patient selection and management of side effects, marking an important step toward refining cancer immunotherapy.

Overall, CAR T-cell therapy offers a beacon of hope for patients with treatment-resistant blood cancers, demonstrating enhanced efficacy and safety profiles. Ongoing research and clinical experience continue to shape its role in standard cancer care, providing new opportunities for successful treatment of previously incurable hematologic malignancies.

Source: [https://medicalxpress.com/news/2025-05-results-car-cell-therapy-leukemia.html]

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Understanding the Newly Recognized Type 5 Diabetes and the Spectrum of Diabetes Types

Learn about the newly recognized Type 5 diabetes linked to early-life malnutrition, alongside other types like Type 1, Type 2, and gestational diabetes. Understanding these forms is crucial for effective treatment and global health strategies.

Molecular Insights into Age-Related Increase in Blood-Brain Barrier Leakiness

New research uncovers how molecular changes cause the blood-brain barrier to become leakier with age, contributing to early memory decline and opening potential therapeutic pathways.

Ending the Aggressive Online Marketing of Baby Formula: A Matters of Public Health

Digital marketing campaigns for baby formula dangerously undermine breastfeeding efforts worldwide. Learn how regulations and support initiatives can protect child health and promote natural nutrition.

Expert Sun Safety Tips from a Skin Cancer Specialist and Physician

Learn essential sun safety tips from a skin cancer specialist to reduce your risk of skin cancer, including using sunscreen, protective clothing, and regular skin checks. Stay protected year-round with these expert guidelines.